Holen Sie sich die Stockscreener-App
2.44
1.74%
0.05
Schlusskurs vom Vortag:
$2.39
Offen:
$2.4
24-Stunden-Volumen:
863.96K
Relative Volume:
0.22
Marktkapitalisierung:
$234.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.4699
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+1.74%
1M Leistung:
+16.90%
6M Leistung:
+35.84%
1J Leistung:
+2.16%
1-Tages-Spanne:
$2.36
$2.4588
1-Wochen-Bereich:
$2.32
$2.49
52-Wochen-Spanne:
$0.9857
$3.67
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.44 | 230.07M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.61 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.05 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.89 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.66 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.36 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
History Review: Is Cabaletta Bio Inc. stock gaining market shareMarket Volume Summary & Daily Technical Forecast Reports - Улправда
Update Report: Is Cabaletta Bio Inc. stock gaining market shareProfit Target & Stepwise Trade Signal Guides - ulpravda.ru
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - ulpravda.ru
Sentiment Watch: Will Cabaletta Bio Inc. stock recover faster than marketChart Signals & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cabaletta Bio Inc. stock continue upward momentumMarket Rally & Capital Efficiency Focused Ideas - Улправда
Will Cabaletta Bio Inc. stock split again soonQuarterly Investment Review & AI Based Buy and Sell Signals - DonanımHaber
Can Cabaletta Bio Inc. stock deliver surprise earnings beatMarket Sentiment Review & Entry and Exit Point Strategies - DonanımHaber
How Cabaletta Bio Inc. stock benefits from global expansionCPI Data & Expert Curated Trade Setups - bolumsonucanavari.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - MSN
Profit Review: Will Cabaletta Bio Inc. stock recover faster than marketRisk Management & Long Hold Capital Preservation Plans - ulpravda.ru
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Yahoo Finance
Cabaletta Bio (CABA) price target increased by 15.31% to 14.41 - MSN
Cabaletta Bio, Inc. $CABA Shares Acquired by Bain Capital Life Sciences Investors LLC - MarketBeat
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment - MSN
CABA Receives FDA Orphan Status for Myasthenia Gravis Treatment - GuruFocus
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Weekly Earnings: Will Cabaletta Bio Inc stock recover faster than marketMarket Sentiment Report & Technical Pattern Based Buy Signals - moha.gov.vn
Cabaletta Bio (CABA) Price Target Increased by 15.31% to 14.41 - Nasdaq
Cabaletta Bio (CABA) Stock Analysis Report | Financials & Insights - Benzinga
Evercore Healthcare Conference - marketscreener.com
Is Cabaletta Bio Inc stock gaining market shareWeekly Trading Summary & Low Risk High Win Rate Picks - BỘ NỘI VỤ
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Form 8-KCurrent report - ADVFN
Jefferies Financial Group Inc. Takes $3.04 Million Position in Cabaletta Bio, Inc. $CABA - MarketBeat
Cabaletta Bio to Present at Key Global Healthcare and Immunology Conferences - MSN
How supply chain issues affect Cabaletta Bio Inc. stock2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Can Cabaletta Bio Inc. stock maintain operating margins2025 Market Overview & Free Real-Time Volume Trigger Notifications - newser.com
Will Cabaletta Bio Inc. stock outperform Nasdaq indexQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
How Cabaletta Bio Inc. stock reacts to oil pricesJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
How Cabaletta Bio Inc. stock performs in rising dollar environmentTrade Risk Assessment & Weekly High Momentum Picks - newser.com
CABALETTA BIO INC (CABA.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Cabaletta Bio Inc. stock could rally in 2025Bond Market & AI Based Buy/Sell Signal Reports - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MyChesCo
Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T - MyChesCo
Tools to assess Cabaletta Bio Inc.’s risk profileJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsLong Setup & Weekly Return Optimization Plans - newser.com
Will Cabaletta Bio Inc. see short term momentumLong Setup & Real-Time Stock Entry Alerts - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsChart Signals & Verified Short-Term Plans - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsRate Cut & Fast Entry High Yield Tips - newser.com
What technical signals suggest for Cabaletta Bio Inc. stock2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Is Cabaletta Bio Inc. stock a contrarian buy2025 Trading Volume Trends & Safe Capital Investment Plans - Fundação Cultural do Pará
Cabaletta Bio Advances in Autoimmune Therapy Development - MSN
Cabaletta Bio FY2025 EPS Estimate Increased by William Blair - MarketBeat
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.July 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.13%
3.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):